507 related articles for article (PubMed ID: 28891448)
21. Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy.
Hardin EA; Chin KM
Drug Des Devel Ther; 2016; 10():3747-3754. PubMed ID: 27895464
[TBL] [Abstract][Full Text] [Related]
22. Selexipag for the treatment of pulmonary arterial hypertension.
Richter MJ; Gall H; Grimminger J; Grimminger F; Ghofrani HA
Expert Opin Pharmacother; 2016 Sep; 17(13):1825-34. PubMed ID: 27467883
[TBL] [Abstract][Full Text] [Related]
23. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V
J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194
[TBL] [Abstract][Full Text] [Related]
24. The prostacyclin pathway in pulmonary arterial hypertension: a clinical review.
Del Pozo R; Hernandez Gonzalez I; Escribano-Subias P
Expert Rev Respir Med; 2017 Jun; 11(6):491-503. PubMed ID: 28399721
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension.
Tanabe N; Ikeda S; Tahara N; Fukuda K; Hatano M; Ito H; Nakayama T; Anzai T; Hashimoto A; Inoue T; Kajinami K; Kihara Y; Kinoshita H; Kuwahara K; Murohara T; Okazaki O; Sakai S; Satoh T; Takeda Y; Takeishi Y; Taniguchi M; Watanabe H; Yamamoto T; Yamauchi-Takihara K; Yoshioka K; Sasayama S
Circ J; 2017 Aug; 81(9):1360-1367. PubMed ID: 28420826
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic drug evaluation of selexipag for the treatment of pulmonary arterial hypertension.
Sardana M; Moll M; Farber HW
Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1513-1520. PubMed ID: 27756196
[TBL] [Abstract][Full Text] [Related]
27. Population Modeling of Selexipag Pharmacokinetics and Clinical Response Parameters in Patients With Pulmonary Arterial Hypertension.
Krause A; Machacek M; Lott D; Hurst N; Bruderer S; Dingemanse J
CPT Pharmacometrics Syst Pharmacol; 2017 Jul; 6(7):477-485. PubMed ID: 28556581
[TBL] [Abstract][Full Text] [Related]
28. Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension.
Asaki T; Kuwano K; Morrison K; Gatfield J; Hamamoto T; Clozel M
J Med Chem; 2015 Sep; 58(18):7128-37. PubMed ID: 26291199
[TBL] [Abstract][Full Text] [Related]
29. Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension.
Chin KM; Rubin LJ; Channick R; Di Scala L; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Simonneau G; Sitbon O; Tapson VF
Circulation; 2019 May; 139(21):2440-2450. PubMed ID: 30982349
[TBL] [Abstract][Full Text] [Related]
30. Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study.
Gaine S; Sitbon O; Channick RN; Chin KM; Sauter R; Galiè N; Hoeper MM; McLaughlin VV; Preiss R; Rubin LJ; Simonneau G; Tapson V; Ghofrani HA; Lang I
Chest; 2021 Jul; 160(1):277-286. PubMed ID: 33545163
[TBL] [Abstract][Full Text] [Related]
31. The selective PGI2 receptor agonist selexipag ameliorates Sugen 5416/hypoxia-induced pulmonary arterial hypertension in rats.
Honda Y; Kosugi K; Fuchikami C; Kuramoto K; Numakura Y; Kuwano K
PLoS One; 2020; 15(10):e0240692. PubMed ID: 33057388
[TBL] [Abstract][Full Text] [Related]
32. Oral treprostinil in the treatment of pulmonary arterial hypertension.
Feldman J; Habib N; Radosevich J; Dutt M
Expert Opin Pharmacother; 2017 Oct; 18(15):1661-1667. PubMed ID: 28922964
[TBL] [Abstract][Full Text] [Related]
33. What Is the Role of Oral Prostacyclin Pathway Medications in Pulmonary Arterial Hypertension Management?
El Yafawi R; Wirth JA
Curr Hypertens Rep; 2017 Oct; 19(12):97. PubMed ID: 29071454
[TBL] [Abstract][Full Text] [Related]
34. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension.
Simonneau G; Torbicki A; Hoeper MM; Delcroix M; Karlócai K; Galiè N; Degano B; Bonderman D; Kurzyna M; Efficace M; Giorgino R; Lang IM
Eur Respir J; 2012 Oct; 40(4):874-80. PubMed ID: 22362844
[TBL] [Abstract][Full Text] [Related]
35. Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study.
Beghetti M; Channick RN; Chin KM; Di Scala L; Gaine S; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Rubin LJ; Simonneau G; Sitbon O; Tapson VF; Galiè N
Eur J Heart Fail; 2019 Mar; 21(3):352-359. PubMed ID: 30632656
[TBL] [Abstract][Full Text] [Related]
36. Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case series.
Fanous SM; Janmohamed M
Am J Health Syst Pharm; 2018 Dec; 75(23):1877-1881. PubMed ID: 30301721
[TBL] [Abstract][Full Text] [Related]
37. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.
Tapson VF; Jing ZC; Xu KF; Pan L; Feldman J; Kiely DG; Kotlyar E; McSwain CS; Laliberte K; Arneson C; Rubin LJ;
Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822
[TBL] [Abstract][Full Text] [Related]
38. Different efficacy of inhaled and oral medications in pulmonary hypertension.
AbuHalimeh BJ; Parambil JG; Tonelli AR
Heart Lung; 2017; 46(4):334-337. PubMed ID: 28527831
[TBL] [Abstract][Full Text] [Related]
39. New paradigm for pulmonary arterial hypertension treatment.
Tamura Y; Channick RN
Curr Opin Pulm Med; 2016 Sep; 22(5):429-33. PubMed ID: 27434819
[TBL] [Abstract][Full Text] [Related]
40. Comparative Safety and Tolerability of Prostacyclins in Pulmonary Hypertension.
O'Connell C; Amar D; Boucly A; Savale L; Jaïs X; Chaumais MC; Montani D; Humbert M; Simonneau G; Sitbon O
Drug Saf; 2016 Apr; 39(4):287-94. PubMed ID: 26748508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
